Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance

Core Viewpoint - Gilead Sciences Inc. reported strong fourth-quarter earnings but provided weak guidance for fiscal 2026, leading to a decline in stock price during extended trading [1][3]. Financial Performance - Gilead reported quarterly earnings of $1.86 per share, surpassing the consensus estimate of $1.81 [2]. - Quarterly revenue reached $7.93 billion, exceeding the Street estimate of $7.69 billion [2]. Product Launch and Growth - The company highlighted the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, along with continued growth for Biktarvy and Descovy [2]. Future Outlook - For fiscal 2026, Gilead expects adjusted EPS in the range of $8.45 to $8.85, compared to the analyst estimate of $8.74 [3]. - Revenue guidance for fiscal 2026 is projected between $29.6 billion and $30 billion, below the analyst estimate of $30.22 billion [3]. Stock Performance - Following the earnings report, Gilead's stock price fell by 2.87% to $143 in extended trading [3].